SLXN (Silexion Therapeutics) EPS (Basic) : $-23.32 (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Silexion Therapeutics EPS (Basic)?

Silexion Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was $-18.27. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $-23.32.

Silexion Therapeutics's EPS (Diluted) for the three months ended in Sep. 2024 was $-18.27. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-23.32.

Silexion Therapeutics's EPS without NRI for the three months ended in Sep. 2024 was $-19.48. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -24.26.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Silexion Therapeutics EPS (Basic) Historical Data

The historical data trend for Silexion Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silexion Therapeutics EPS (Basic) Chart

Silexion Therapeutics Annual Data

Trend

Dec22

Dec23

EPS (Basic)

-3.55

-5.46

Silexion Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial			-0.87	-1.91	-1.52	-1.63	-18.27

Silexion Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Silexion Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-4.942	-	0)	/	0.906
	=	-5.45

Silexion Therapeutics's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-11.851	-	0)	/	0.648
	=	-18.29

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.32

Silexion Therapeutics (NAS:SLXN) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Silexion Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Silexion Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Silexion Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silexion Therapeutics Corp (NAS:SLXN) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Ha mayan Street, Modi in-Maccabim-Reut, ISR, 7177871

Website

https://www.silexion.com

Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.